Objective: This is the first study examining the value of CONUT score in assessing malnutrition among acute pulmonary embolism patients. We showed that the presence of malnutrition defined by the CONUT score predicts in-hospital mortality following acute pulmonary embolism.The association between the nutritional status and outcomes in pulmonary embolism is unclear. Therefore, we aimed to assess the association between Controlling Nutritional Status (CONUT) score, and in-hospital mortality in patients with acute pulmonary embolism.
Subject and Methods: We retrospectively reviewed the records of all adult patients with acute pulmonary embolism hospitalized through our ED. Demographic, clinical, and laboratory data on admission were recorded. Nutritional status was assessed with the CONUT score, which is calculated by the albumin, total cholesterol, and lymphocyte counts. The primary endpoint of the study was in-hospital mortality.
Results: A total of 308 consecutive patients (mean age 68.2 ± 12.9 years, 53.9 % female) were included, and 35 of the patients (11.4%) died during their in-hospital course. Multivariate analysis showed that pulmonary embolism severity index >148 (OR 3.12, 95% CI 1.65-8.81, p< 0.001), presence of heart failure (1.25, 95% CI 1.08-1.78, p= 0.03), and CONUT score> 4 (OR 1.39, 95% CI 1.146-3.424, p= 0.015) were independent predictors of in-hospital mortality.
Conclusion: The present study indicates that the presence of malnutrition defined by the CONUT score predicts in-hospital mortality following acute pulmonary embolism.
Background:
Indications and appropriateness of aspirin use have not been well investigated in Turkey.
Aims:
To investigate the prescription patterns and appropriateness of aspirin in a real-world clinical setting.
Study Design:
Cross-sectional study.
Methods:
The Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study (ASSOS) is a cross-sectional and multicenter study that included 5007 consecutive patients aged 18 or over who presented to 30 different cardiology outpatient clinics from 14 cities throughout Turkey. Only patients using aspirin (80-325 mg) were included. The study population was divided into 2 groups regarding the use of aspirin: primary prevention (PP) group and secondary prevention (SP) group. The indication of aspirin use was evaluated following the 2016 European Society of Cardiology (ESC) and the 2016 United States Preventative Services Task Force (USPTF) guidelines in the PP group.
Results:
A total of 5007 patients (mean age 62.15 ± 11.05, 39% female) were enrolled. The PP group included 1132 (22.6%) patients, and the SP group included 3875 (77.4%) patients. Of the 1132 patients, inappropriate use of aspirin was determined in 100% of the patients according to the ESC guidelines, and 71% of the patients according to the USPTF guidelines. Multivariate logistic regression analysis showed age OR: 0.98 CI (0.97-0.99)
P
= .037, smoking OR: 0.60 CI (0.44-0.82)
P
= .001, heart failure OR: 2.11 CI (1.14-3.92)
P
= .017, hypertension OR: 0.51 CI (0.36-0.74)
P
< .001, diabetes mellitus OR: 0.34 CI (0.25-0.47)
P
< .001, oral anticoagulant use OR: 3.01 CI (1.10-8.25)
P
= .032, and female sex OR: 2.73 CI (1.96-3.80)
P
< .001 were independent predictors of inappropriate aspirin use in PP patients.
Conclusion:
Although there are considerable differences between the USPTF and the ESC guidelines with respect to recommendations for aspirin use in PP, inappropriate use of aspirin in Turkey is frequent in real-world practice for both guidelines. Besides, heart failure, oral anticoagulant use, and the female sex of the patients were independent predictors of inappropriate use of aspirin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.